⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3771818 | 0.72 | TSHR (0.39) | — | |
| SCHEMBL968723 | 0.69 | — | — | |
| SCHEMBL7790194 | 0.67 | — | — | |
| SCHEMBL4405064 | 0.65 | HSD17B10 (0.37) | — | |
| SCHEMBL3085542 | 0.65 | TDP1 (0.45) | — | |
| SCHEMBL756107 | 0.62 | — | — | |
| SCHEMBL95391 | 0.56 | — | — | |
| SCHEMBL8180839 | 0.56 | — | — | |
| Ammonia Solution, Strong SCHEMBL9146129 | 0.53 | CA1 (0.36) | — | |
| SCHEMBL30104 | 0.52 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8314217-B2 | Cross-linked glycopeptide-cephalosporin antibiotics | THERAVANCE, INC. (US) | 2012-11-20 | — | — | US | disclosed |
| US-20110224130-A1 | CROSS-LINKED GLYCOPEPTIDE-CEPHALOSPORIN ANTIBIOTICS | THERAVANCE, INC. (US) | 2011-09-15 | — | — | US | disclosed |
| US-7871997-B2 | Cephalosporin compounds | THERAVANCE, INC. (US) | 2011-01-18 | — | — | US | disclosed |
| EP-1633759-B1 | CROSS-LINKED GLYCOPEPTIDE-CEPHALOSPORIN ANTIBIOTICS | THERAVANCE INC (US) | 2009-12-02 | — | — | EP | disclosed |
| US-20080103299-A1 | Cross-linked glycopeptide - cephalosporin antibiotics | THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC | 2008-05-01 | — | — | US | disclosed |
| EP-1644382-B1 | CROSS-LINKED GLYCOPEPTIDE-CEPHALOSPORIN ANTIBIOTICS | THERAVANCE INC (US) | 2008-03-05 | — | — | EP | disclosed |
| US-7332471-B2 | Cross-linked glycopeptide-cephalosporin antibiotics | THERAVANCE, INC. (US) | 2008-02-19 | — | — | US | disclosed |
| US-7279458-B2 | Cross-linked glycopeptide-cephalosporin antibiotics | THERAVANCE, INC. (US) | 2007-10-09 | — | — | US | disclosed |
| US-20060189517-A1 | Cross-linked glycopeptide-cephalosporin antibiotics | THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC | 2006-08-24 | — | — | US | disclosed |
| US-7067481-B2 | Cross-linked glycopeptide-cephalosporin antibiotics | THERAVANCE, INC. (US) | 2006-06-27 | — | — | US | disclosed |
| US-7067482-B2 | Cross-linked glycopeptide-cephalosporin antibiotics | THERAVANCE, INC. (US) | 2006-06-27 | — | — | US | disclosed |
| US-20060128612-A1 | Cross-linked glycopeptide-cephalosporin antibiotics | THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC | 2006-06-15 | — | — | US | disclosed |
| EP-1644382-A2 | CROSS-LINKED GLYCOPEPTIDE-CEPHALOSPORIN ANTIBIOTICS | Theravance, Inc. (US) | 2006-04-12 | — | — | EP | disclosed |
| EP-1633759-A1 | CROSS-LINKED GLYCOPEPTIDE - CEPHALOSPORIN ANTIBIOTICS | Theravance, Inc. (US) | 2006-03-15 | — | — | EP | disclosed |
| US-20050026818-A1 | Cross-linked glycopeptide-cephalosporin antibiotics | THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC | 2005-02-03 | — | — | US | disclosed |
| WO-2005005436-A2 | CROSS-LINKED GLYCOPEPTIDE-CEPHALOSPORIN ANTIBIOTICS | THERAVANCE, INC. (US) | 2005-01-20 | — | — | WO | disclosed |
| US-20040266666-A1 | Cross-linked glycopeptide-cephalosporin antibiotics | THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC | 2004-12-30 | — | — | US | disclosed |
| WO-2004113350-A1 | CROSS-LINKED GLYCOPEPTIDE - CEPHALOSPORIN ANTIBIOTICS | THERAVANCE, INC. (US) | 2004-12-29 | — | — | WO | disclosed |